A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

NCT07340424 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Advanced Metastatic Triple-negative Breast Cancer (mTNBC)

Interventions

DRUG: 225Ac-TR2205 Injection

Sponsor

Xiaorong Sun